| Name | Title | Contact Details |
|---|
Rallybio is a privately-held development-stage biotechnology company incorporated in January 2018. Our ambition is to create a leading biotechnology organization that transforms the lives of patients with devastating disease, built around people with an outstanding track record in pharmaceutical research and development. We will identify and accelerate the development of highly-promising drug candidates that have strong biological rationales and that can be addressed using the well-validated therapeutic modalities of small molecules, engineered proteins, and antibodies. A part of the Technology Incubation Program at the University of Connecticut in Farmington, CT, we continue to expand our drug acquisition and development capabilities through the assembly of a team of individuals with an outstanding track record in pharmaceutical research, development, and a strong understanding of the financial components of the industry. This seasoned team enables us to search for and evaluate assets using a series of robust clinical and commercial filters that will allow us to identify and acquire a portfolio of high-quality small molecule and protein-based assets in the late discovery to early clinical stages of drug development. Named by FierceBiotech as one of its “Fierce 15” Biotech Companies of 2018, the company was recognized as being among “the most promising private biotech startups”. Rallybio has earned the support of highly-respected investors in the bioscience sector and announced in April 2018 that it had secured $37.0 million in Series A funding with lead financing from 5AM Ventures, Canaan Partners, and New Leaf Venture Partners, and additional public-sector participation from Connecticut Innovations.
Tomtec Inc is a Hamden, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Trinity Biomedical is a Menomonee Falls, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OncoSec Medical Inc. is a biopharmaceutical company developing its ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical’s core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-modulating agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec’s clinical programs currently include three Phase 2 trials targeting metastatic melanoma Merkel cell carcinoma and cutaneous T-cell lymphoma conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in these indications it is also investigating additional indications and combination therapeutic approaches.
NovaTec Consultants, Inc. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.